PKC Activator Dosing for ALS Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are currently no effective medical interventions for amyotrophic lateral sclerosis (ALS) or other motor neuron diseases, which leads to progressive muscular weakness, atrophy, and loss of voluntary muscle movement, ultimately resulting in severe disability and death.
Innovation Solution
Administering a therapeutically effective amount of a PKC activating compound, such as bryostatin-1, macrocyclic lactones, polyunsaturated fatty acids, or growth factors, to a subject in need thereof to mitigate or prevent the symptoms of ALS or other motor neuron diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no medical intervention is used for ALS, then the disease progresses naturally causing muscular weakness and atrophy, but administering PKC activating compounds may mitigate progression and improve quality of life
Solution Approach 1:
The patent changes the biochemical parameter by activating PKC (protein kinase C) signaling pathway through administration of PKC activating compounds. This parameter change in cellular signaling leads to neuroprotection and mitigation of ALS progression, transforming the disease course from progressive degeneration to stabilized or improved neural function.
2Reliability
If PKC activating compounds are administered to treat ALS, then neuroprotection and synaptogenesis are promoted, but the dosing regimen becomes complex with multiple dosage adjustments
Solution Approach 1:
The patent implements periodic dosing action with an initial loading dose followed by maintenance doses at reduced frequencies. Specifically, the regimen uses a loading dose on Day 1, then maintenance doses on Days 8, 15, 22, and subsequent monthly doses. This periodic action pattern simplifies the dosing strategy while maintaining therapeutic effectiveness for neuroprotection and synaptogenesis.
Data Source
AI summary
A method for treating or preventing amyotrophic lateral sclerosis (ALS) or other motor neuron disease in a subject, the method comprising administering to the subject a PKC activating compound (e.g., a bryostatin, such as bryostatin-1, or a bryolog) in a therapeutically effective amount to treat or prevent the motor neuron disease by activating PKC in the subject. The ALS may be, for example, classical ALS, primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), and progressive bulbar palsy (PBP). The PKC activating compound may be administered at an initial loading dose of about 15, 24, or 48 micrograms weekly in the first one week or consecutive two or three weeks, followed by doses of about 12, 20, or 40 micrograms alternately every two or three weeks for at least 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 24, or 30 total weeks.